Navigation Links
Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the 21st Annual Piper Jaffray Health Care Conference at The New York Palace in New York City on December 1, 2009 at 1:00 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel(TM) (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading ... , published its 2017 ranking of the Best-Equipped Hospitals ... data analysis from GHI,s hospitals database for Latin America ... region. The GHI database covers 86% of the hospitals in ... data points for each institution in key areas such as ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. ... the latest advancements in his field by attending numerous CE courses each year. ...
(Date:5/24/2017)... ... , ... If you are thinking of a visit to San Francisco , fall is ... perfect time to visit. , Business Architecture Associates is pleased to offer 5 days of ... a 4-½ day package for individuals, and as 4-½ day corporate package for up to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com ... food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ... process. As a result, labels need to deliver simple, transparent and clear messaging. ...
(Date:5/23/2017)... SANTA CLARA, CA (PRWEB) , ... May 23, 2017 , ... ... government and financial organizations, today announced CIO Applications magazine has named the company a ... of its innovative use of the Cloud to help organizations simply and proactively address ...
(Date:5/23/2017)... N.Y. (PRWEB) , ... May 23, 2017 , ... New ... Public Health Crisis Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on ... Staunton Foundation for the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a ...
Breaking Medicine News(10 mins):